Clinical Trial: Stiripentol in Dravet Syndrome

Study Status: No longer available
Recruit Status: No longer available
Study Type: Expanded Access




Official Title: Compassionate Use of Stiripentol in Intractable Epilepsy Due to Dravet Syndrome

Brief Summary: The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.